Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOERXK)

• Drug Name: L-751250 Drug Info
• Synonyms: Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB
• Cross-matching ID:
  PubChem CID: 448991
  ChEBI ID: CHEMBL23254
  CAS Number: CAS 212844-54-7
  TTD Drug ID: D0WS1V

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Mitophagy	-1.67	4.15e-2	56/68 (82.35%)	CSNK2A2;TBC1D17;TBK1;...
Toll-like receptor signaling pathway	-1.67	4.27e-2	94/104 (90.38%)	TBK1;IFNA1;TNF;...
Lysosome	-1.68	4.49e-2	115/128 (89.84%)	CTSG;ATP6V0D1;GGA3;...
Viral protein interaction with cytokine and cytokine re...	-1.68	4.72e-2	84/100 (84%)	CCL21;TNF;IL2RA;...
Thyroid hormone synthesis	-1.68	4.99e-2	66/75 (88%)	PDIA4;GPX5;ITPR1;...
Complement and coagulation cascades	-1.78	1.45e-2	76/85 (89.41%)	F2;CPB2;C1R;...
Intestinal immune network for IgA production	-1.79	1.55e-2	38/48 (79.17%)	HLA-DRB1;CXCL12;AICDA;...
Mineral absorption	-1.81	1.11e-2	48/60 (80%)	ATP2B4;HEPH;HMOX2;...
Staphylococcus aureus infection	-1.82	1.19e-2	72/95 (75.79%)	HLA-DRB1;ITGAM;KRT33B;...
Graft-versus-host disease	-1.83	1.03e-2	32/42 (76.19%)	HLA-DQB1;KIR3DL1;KIR2DL1;...
Pancreatic secretion	-1.84	1.13e-2	87/102 (85.29%)	PLCB2;ATP2B3;PNLIPRP1;...
Hematopoietic cell lineage	-1.84	1.24e-2	90/99 (90.91%)	CD3G;CD36;ITGB3;...
Galactose metabolism	-1.90	8.60e-3	26/31 (83.87%)	LCT;GLB1;PFKM;...
Neutrophil extracellular trap formation	-1.91	9.67e-3	101/189 (53.44%)	ITGB3;HDAC3;SELP;...
Autoimmune thyroid disease	-1.93	8.84e-3	46/53 (86.79%)	CD80;HLA-F;HLA-E;...
Asthma	-1.94	7.74e-3	25/31 (80.65%)	HLA-DMB;PRG2;RNASE3;...
Systemic lupus erythematosus	-1.95	0.00e+0	45/135 (33.33%)	C8G;HLA-DOA;TNF;...
Viral myocarditis	-1.96	0.00e+0	53/60 (88.33%)	HLA-DRB1;MYH6;ABL1;...
Nicotine addiction	-1.98	0.00e+0	32/40 (80%)	GRIN1;GABRA1;CHRNB2;...
Allograft rejection	-1.99	0.00e+0	32/38 (84.21%)	CD80;HLA-F;HLA-E;...
Ferroptosis	-2.16	0.00e+0	36/41 (87.8%)	GPX4;ACSL3;ACSL4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H, 24H	Show ▼